Compare XOMA & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XOMA | PACB |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.6M | 419.8M |
| IPO Year | N/A | 2010 |
| Metric | XOMA | PACB |
|---|---|---|
| Price | $41.67 | $1.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $52.50 | $1.67 |
| AVG Volume (30 Days) | 371.4K | ★ 6.2M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $24.59 | $11.32 |
| Revenue Next Year | N/A | $12.14 |
| P/E Ratio | $29.64 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $22.29 | $0.85 |
| 52 Week High | $42.81 | $2.73 |
| Indicator | XOMA | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 66.49 | 31.12 |
| Support Level | $24.38 | N/A |
| Resistance Level | $42.00 | $1.43 |
| Average True Range (ATR) | 0.66 | 0.11 |
| MACD | -0.32 | -0.05 |
| Stochastic Oscillator | 63.02 | 2.34 |
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.